دورية أكاديمية

Enhancement of lomefloxacin Hcl ocular efficacy via niosomal encapsulation: in vitro characterization and in vivo evaluation.

التفاصيل البيبلوغرافية
العنوان: Enhancement of lomefloxacin Hcl ocular efficacy via niosomal encapsulation: in vitro characterization and in vivo evaluation.
المؤلفون: Khalil RM; a Pharmaceutical Technology Department, National Research Centre , Cairo , Egypt., Abdelbary GA; b Department of Pharmaceutics , Faculty of Pharmacy, Cairo University , Cairo , Egypt and., Basha M; a Pharmaceutical Technology Department, National Research Centre , Cairo , Egypt., Awad GEA; c Chemistry of Natural and Microbial Product Department , National Research Centre , Cairo , Egypt., El-Hashemy HA; a Pharmaceutical Technology Department, National Research Centre , Cairo , Egypt.
المصدر: Journal of liposome research [J Liposome Res] 2017 Dec; Vol. 27 (4), pp. 312-323. Date of Electronic Publication: 2016 Jun 30.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Informa Healthcare Country of Publication: England NLM ID: 9001952 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-2394 (Electronic) Linking ISSN: 08982104 NLM ISO Abbreviation: J Liposome Res Subsets: MEDLINE
أسماء مطبوعة: Publication: London : Informa Healthcare
Original Publication: New York, N.Y. : Dekker, c1988-
مواضيع طبية MeSH: Eye/*drug effects , Fluoroquinolones/*chemistry , Fluoroquinolones/*pharmacology , Liposomes/*chemistry, Animals ; Anti-Bacterial Agents/chemistry ; Anti-Bacterial Agents/therapeutic use ; Chemistry, Pharmaceutical/methods ; Cholesterol/chemistry ; Conjunctivitis, Bacterial/drug therapy ; Conjunctivitis, Bacterial/microbiology ; Drug Carriers/chemistry ; Drug Liberation ; Drug Stability ; Fluoroquinolones/administration & dosage ; Fluoroquinolones/therapeutic use ; Humans ; Hydrogen-Ion Concentration ; Male ; Microscopy, Electron, Transmission/methods ; Particle Size ; Rabbits ; Staphylococcus aureus/drug effects ; Surface Properties ; Surface-Active Agents/chemistry
مستخلص: The aim of this study is to develop and evaluate niosomal dispersions loaded with the hydrophilic drug; lomefloxacin Hcl (LXN) for the management of ocular bacterial conjunctivitis. LXN-loaded niosomes were prepared by the thin film hydration method following a full factorial formulation design. Two independent variables were evaluated: the type of surfactant (X1) and the surfactant:cholesterol ratio (X2). The dependent variables comprised entrapment efficiency (EE%: Y1), particle size (PS: Y2) and zeta potential (ZP: Y3). The optimum formulation, N-LXN14 (Tw60: CH, 1:1), was spherical in shape and exhibited EE% of 68.41 ± 0.07, PS of 176.0 ± 0.98 and ZP of -40.70 ± 2.20 with a sustained release profile over 8 hours following the Higuchi model. N-LXN14 proved good physicochemical stability under refrigeration up to 3 months. Ocular irritancy test showed no signs of ocular toxicity, confirming the safety and suitability for ocular application. Microbiological evaluation of the antibacterial effect of N-LXN14 was conducted using the susceptibility test and through the induction of topical conjunctivitis by Staphylococcus aureus (S. aureus) followed by topical therapy. Susceptibility test manifested significantly higher percent inhibition of S. aureus and higher AUC 0-12 h of N-LXN14 (604.59 ± 0.05) compared to the commercial product (126.25 ± 0.049). Both clinical observation and colony count of the infected eyes after eight days of treatment demonstrated significant improvement in therapeutic response. The infected eyes were completely healed with eradication of S. aureus. In conclusion, the results showed that LXN niosomal dispersions may serve as a promising superior ocular delivery system in the treatment of bacterial conjunctivitis.
فهرسة مساهمة: Keywords: Conjunctivitis; lomefloxacin Hcl; microbiological evaluation; niosomes; ocular delivery
المشرفين على المادة: 0 (Anti-Bacterial Agents)
0 (Drug Carriers)
0 (Fluoroquinolones)
0 (Liposomes)
0 (Surface-Active Agents)
97C5T2UQ7J (Cholesterol)
L6BR2WJD8V (lomefloxacin)
تواريخ الأحداث: Date Created: 20160601 Date Completed: 20181112 Latest Revision: 20220408
رمز التحديث: 20231215
DOI: 10.1080/08982104.2016.1191022
PMID: 27241274
قاعدة البيانات: MEDLINE
الوصف
تدمد:1532-2394
DOI:10.1080/08982104.2016.1191022